Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 7/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.49 |
| ▸ | FABP2 | P12104 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1808069 | 0.92 | ABCB11 (0.56) | ELANESMN1; SMN2MAPTLMNAPPARA | |
| SCHEMBL21991771 | 0.87 | MMP2 (0.53) | HPGDSMN1; SMN2MAPTLMNAL3MBTL1 | |
| SCHEMBL10339728 | 0.84 | ELANE (0.66) | ELANEHPGDSMN1; SMN2MAPTLMNA | |
| Urethane SCHEMBL21771921 | 0.84 | CYP1A2 (0.49) | HPGDSMN1; SMN2MAPTLMNAPPARA | |
| SCHEMBL21991472 | 0.84 | NPC1 (0.61) | SMN1; SMN2MAPTLMNAL3MBTL1PPARA | |
| SCHEMBL6451238 | 0.82 | ALDH1A1 (0.55) | SMN1; SMN2MAPTLMNAL3MBTL1TSHR | |
| SCHEMBL21991481 | 0.81 | HPGD (0.68) | ELANEHPGDSMN1; SMN2MAPTLMNA | |
| SCHEMBL929726 | 0.81 | KMT2A (0.45) | ELANESMN1; SMN2LMNAL3MBTL1CYP1A2 | |
| SCHEMBL21991753 | 0.80 | MAOB (0.60) | MAPTLMNAL3MBTL1 | |
| SCHEMBL3789020 | 0.80 | HSD17B10 (0.53) | SMN1; SMN2MAPTTSHRKMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | ELANE 30/4885HPGD 765/4885SMN1; SMN2 3122/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | ELANE 30/4885HPGD 765/4885SMN1; SMN2 3122/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | ELANE 30/4885HPGD 765/4885SMN1; SMN2 3122/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | ELANE 30/4885HPGD 765/4885SMN1; SMN2 3122/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | ELANE 30/4885HPGD 765/4885SMN1; SMN2 3122/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | ELANE 30/4885HPGD 765/4885SMN1; SMN2 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.